Exosomes have great potential to deliver drugs due to its low antigenicity. However, low yield and lack of targeting capability have hindered its application. This study aimed at creating a biomanufacturing platform of cancer-targeted exosomes. First, we created a scalable, high-productivity, cell line-based monoclonal antibody tagged exosomes (mAb-Exo) production process, and characterized the product with transmission electron microscopy, NanoSight and Western blotting. Second, we confirmed the cancer-specific targeting using flow cytometry and confocal laser scanning microscopy and using live animal imaging system. Finally, we loaded Romidepsin, a histone deacetylase inhibitor, in mAb-Exo and validated the targeted drug delivery capability in tumor xenograft animal model by testing the cancer targeting specificity and anti-cancer efficacy. We developed new technique enabling targeted drug delivery.
